astrazeneca glp 1 AstraZeneca's Bydureon gets a facelift, but can it stand out in a GLP-1 market that's only getting tougher? GLP-1 Market Key Players Analysis
Description
Whilst GLP-1 medications are not currently licensed specifically for binge eating disorder in the UK, emerging research is exploring their potential therapeutic role

You have your 365-Day Love It or Your Money Back Guarantee
Li: We need to understand how to help patients lose weight while preserving muscle, maintaining nutritional health and supporting mental well-being

Bringing addiction treatment 'inside the house of medicine' In addition to food addiction, GLP-1s show promise for opioid, alcohol and nicotine addiction Early studies suggest that GLP-1s may be effective in treating opioid, alcohol and nicotine addiction

Diabetes care 29 , 435449 (2006)
